TP53 and in situ carcinoma: In literature FGFR3 and TP53 mutations were initially thought to be mutually exclusive as FGFR3 mutations were associated with pTa and LG tumors (“papillary pathway”), whereas the TP53 mutations were often found in invasive and HG carcinomas (“CIS/invasive pathway”) [17,18].